Press Releases
| [+] |
September 18, 2009 Wyeth and Ambrx Form Multi-target Alliance to Leverage Recent Ambrx Biologics Platform Advances COLLEGEVILLE, PA and SAN DIEGO, CA – September 18, 2009 – Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE) and Ambrx Inc. today announced the formation of a worldwide alliance to discover, develop, and commercialize protein drug candidates for three undisclosed targets inmultiple therapeutic areas. The alliance will capitalize on A… Read More |
 |
| [+] |
February 24, 2009 Ambrx and Merck Serono Expand Collaboration Through ARX424 Multiple Sclerosis Drug Development Alliance San Diego, CA – February 24, 2009 – Ambrx Inc, and Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced a global strategic collaboration to develop and commercialize Ambrx’s ARX424 preclinical product candidate for the treatment of multiple sclerosis. ARX424 was created by Ambrx through the a… Read More |
Articles
- April 1, 2005
Unnatural Amino Acid Could Prove Boon for Protein Therapeutics
Science Magazine - March 14, 2005
Giving Biotechnology A Chemical Push
Chemical & Engineering News - March 14, 2005
Watching Peptide Drugs Grow Up
Chemical & Engineering News - January 12, 2004
The Code Breakers
Bio-IT World - October 6, 2003
Executive Profile - RICHARD D. DIMARCHI
SD Business Journal (paid access) - September 29, 2003
Ambrx Inc. Lands $12.5M in First-Round Funding
SD Business Journal (paid access) - September 23, 2003
First-Round Financing of $12.5M Puts Ambrx On Development Path
BioWorld Today - September 22, 2003
Schultz seeks another success with Ambrx
The Daily Deal
